PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.07
0.06 - 0.24
1.89M / 3.59M (Avg.)
-1.60 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-80.45%
Negative EBIT growth while SMR.AX is at 27.94%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-80.45%
Negative operating income growth while SMR.AX is at 27.94%. Joel Greenblatt would press for urgent turnaround measures.
5682.20%
Positive net income growth while SMR.AX is negative. John Neff might see a big relative performance advantage.
5320.00%
EPS growth above 1.5x SMR.AX's 32.79%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
5326.67%
Diluted EPS growth above 1.5x SMR.AX's 32.79%. David Dodd would see if there's a robust moat protecting these shareholder gains.
4.50%
Share change of 4.50% while SMR.AX is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
4.34%
Diluted share change of 4.34% while SMR.AX is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
42.92%
OCF growth of 42.92% while SMR.AX is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
-41.89%
Negative FCF growth while SMR.AX is at 91.38%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-100.00%
Negative 10Y revenue/share CAGR while SMR.AX stands at 0.00%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-100.00%
Negative 5Y CAGR while SMR.AX stands at 0.00%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-100.00%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
73.70%
OCF/share CAGR of 73.70% while SMR.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
73.70%
OCF/share CAGR of 73.70% while SMR.AX is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
73.70%
3Y OCF/share CAGR of 73.70% while SMR.AX is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
162.86%
10Y net income/share CAGR of 162.86% while SMR.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
162.86%
Net income/share CAGR of 162.86% while SMR.AX is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
162.86%
Positive short-term CAGR while SMR.AX is negative. John Neff would see a clear advantage in near-term profit trajectory.
-26.50%
Negative equity/share CAGR over 10 years while SMR.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-26.50%
Negative 5Y equity/share growth while SMR.AX is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-26.50%
Negative 3Y equity/share growth while SMR.AX is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.30%
We have a declining book value while SMR.AX shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
328.76%
We expand SG&A while SMR.AX cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.